Pearl Daily Medicine: Belzutifan (Welireg)


Belzutifan is indicated for the treatment of adult patients with von Hippel-Lindau disease who require treatment for associated renal carcinoma, central nervous system hemangioblastomas or pancreatic neuroendocrine tumors.

Medication Pearl of the day: Belzutifan (Welireg)

Indication: Belzutif is a hypoxia-inducible factor inhibitor indicated for the treatment of adult patients with von Hippel-Lindau disease who require treatment for associated renal carcinoma, central nervous system hemangioblastomas or pancreatic neuroendocrine tumors, not requiring no immediate surgery.

Overview:

  • Dosage: The recommended dosage of belzutifanis 120 mg taken orally once daily with or without food.
  • Dosage forms:Tablets 40 mg.
  • Adverse Events (AEs): The most common AEs (≥ 25%), including laboratory abnormalities, were decreased hemoglobin, anemia, fatigue, increased creatinine, headache, dizziness, increased blood blood sugar and nausea.
  • Action mechanism: Belzutifan is a hypoxia-inducible factor 2 alpha (HIF-2α) inhibitor. HIF-2α is a transcription factor that plays a role in the detection of oxygen by regulating genes that promote adaptation to hypoxia.
  • Maker: Merck

Sources:

About Michael Bill

Check Also

Gwen shares a weird article about drugs and antidepressants

Sister Wives’ Gwendlyn Brown is freaking out her followers after a rather thoughtless post on …